Formulation Development
FORMULATION FORUM - LIPIDSOL®: Liposomes - Chemistry, Properties & Applications of Lipid Nanoparticles
Jim Huang, PhD, and Shaukat Ali, PhD, describe their LNP platform as well as the latest trends in LNPs as more and more novel therapeutic modalities discovered can’t be handled by traditional microemulsions or nanoemulsions.
SPECIAL FEATURE - Parenteral Drug Delivery: Could a Dose of AI Improve Development?
Contributor Cindy H. Dubin speaks with several innovative companies to highlight the strides they are currently making toward improving dose accuracy, integrating design safety, and accelerating time to market.
IMMUNOLOGY - Innovation Gathers Momentum Amid New Scientific & Technological Breakthroughs
Patrick Larcier, PhD, says research is entering a new era in immunology with treatments for pathologies that previously had few or no options and looks at the latest trends and what is on the horizon for 2023 and beyond.
ION EXCHANGE EXCIPIENTS - Tackling Patient Compliance With Oral Drug Formulations Using Ion Exchange Resins
Amie Gehris explains how IERs solve various pharmaceutical formulation issues, including decreasing the bitter taste of many pharmaceutical drugs, improving patient outcomes by supporting compliance to treatment regimens, and providing new revenue streams for pharmaceutical companies.
EXECUTIVE INTERVIEW - Novadip Biosciences: Developing a New Class of Regenerative Tissue Products to Accelerate Healing of Critical Size Bone Defects, Trauma & Spinal Problems
Denis Dufrane, MD, PhD, Chief Executive Officer, and Founder of Novadip Biosciences, discusses his company’s innovative approach to tissue regeneration technology.
DRUG-ELUTING SYSTEMS - Introducing Drugs to Silicone & Controlling Elution Rates
Zach Fletcher explains how an experienced manufacturing partner can help therapy developers quickly identify solutions and develop manufacturing and formulation methods for use in many applications.
EXECUTIVE INTERVIEW - Ascendia Pharmaceuticals: Innovative Solutions to Challenging Problems
Jim Huang, PhD, CEO and Founder of Ascendia Pharmaceuticals, discusses how his company expanded its people, capabilities, and facilities to meet and exceed customer expectations from early to late-state development and how this investment allows Ascendia to continue be an expert in sophisticated formulations, as well as cGMP sterile and non-sterile clinical trial and commercial manufacturing.
VACCINE TECHNOLOGY - Solving the Challenges & Introducing New Strategies for Influenza & COVID-19 Protection
Paul Radspinner, MBA, and Pamuk Bilsel, PhD, say with a combination vaccination strategy, the biopharma industry could truly solve the efficacy, durability, and drift problems of current influenza and COVID-19 vaccines.
WHITEPAPER - Extrusion-Spheronization, Engineered for Today’s Controlled Release Forms
Synchronizing and controlling API delivery, extrusion-spheronization (E-S) offers pharmaceutical companies a robust technique to manufacture today’s most complex therapeutics. Manufacturing oral….
Ovid Therapeutics Announces Collaboration With Graviton Bioscience, Proven Developers of Selective ROCK2 Inhibitors
Ovid Therapeutics Inc. and Graviton Bioscience Corporation recently announced a collaboration agreement to innovate novel medicines they believe will significantly change….
Aldevron Announces Expansion of mRNA Production Capability
Aldevron recently announced it will expand its mRNA production capabilities to include lipid nanoparticle (LNP) encapsulation and aseptic fill-finish capabilities enabling mRNA cGMP manufacturing services from…
Immutep Receives Approval to Initiate INSIGHT-005 Trial Evaluating Eftilagimod Alpha & Anti-PD-L1 Therapy
Immutep Limited recently announced it has received regulatory approval from the Paul-Ehrlich-Institut (PEI), German Federal Institute for Vaccines and Biomedicines, to initiate INSIGHT-005, an investigator-initiated,…
Biomea Fusion Announces FDA Clearance of INDA for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia
Biomea Fusion, Inc. recently announced the US FDA has cleared the company's Investigational New Drug (IND) application to begin a Phase 1 trial (COVALENT-103) of…
Soligenix Enters Exclusive Option Agreement With Silk Road Therapeutics for Rights to Topical Pentoxifylline Designed to Treat Behçet’s Disease
Soligenix, Inc. recently announced it has entered into an exclusive option agreement with Silk Road Therapeutics granting the company the right to acquire a novel…
Combangio Awarded $15 Million to Support Ongoing KPI-012 Program for the Treatment of PCED
Kala Pharmaceuticals, Inc. recently announced the California Institute for Regenerative Medicine (CIRM) has awarded Combangio, Inc., a wholly owned subsidiary of Kala, a $15-million grant…
Tavros Therapeutics & OpenBench Expand Strategic Collaboration for Small Molecule Drug Discovery
Multi-target collaboration leverages Tavros’ proprietary functional genomic discovery program and OpenBench’s screening platform, partnership streamlines drug development for novel cancer therapies….
Aptamers Market is Expected to Reach $342 million
The aptamers industry has been growing steadily in recent years, and is expected to continue to do so in the near future. This can be…
BullFrog AI Partners With the Sage Group to Explore JV Opportunities to Advance its Oncology Assets
BullFrog AI Holdings, Inc. recently announced a strategic partnership with the Sage Group, a leader in the provision of strategic and transactional advice to healthcare and…
Plasticell & LambdaGen Form Collaboration to Develop iPSC-Derived CAR-NK Allogeneic Cancer Immunotherapies
Plasticell Ltd recently announced today it has entered into a strategic collaboration with Singapore-based LambdaGen. Together, the two companies will exploit genome-editing technologies based on…
Arrowhead Pharmaceuticals’ Proprietary Pulmonary TRiM Platform Achieves High Levels of Target Gene Knockdown & Long Duration of Effect
Interim Results from Ongoing ARO-RAGE Phase 1/2 Study Demonstrate up to 90% Serum sRAGE Reduction with Mean Maximum Reduction of 80% after Two Doses….
